Skip to main content

Posts tagged with "In Silico"

  • Clinical Trials

    The Virtual Clinical Trial: Not Quite Around the Corner

    Here’s one of those “Drug Discovery of. . .the. . .Future-ure-ure-ure” articles in the popular press. (I need a reverb chamber to make that work property). At The Atlantic, they’re talking with “medical futurists” and coming up with this: The idea is to combine big data and computer simulations—the kind an engi… Read More
  • Drug Assays

    Hosed-Up X-Ray Structures: A Big Problem

    X-ray crystallography is great stuff, no doubt about it. But it’s not magic. It takes substantial human input to give a useful structure of a ligand bound to a protein – there are decisions to be made and differences to be split. It’s important to emphasize, for those of us who are not crystallographers, that… Read More
  • Drug Assays

    Predicting New Targets – Another Approach

    So you make a new chemical structure as part of a drug research program. What’s it going to hit when it goes into an animal? That question is a good indicator of the divide between the general public and actual chemists and pharmacologists. People without any med-chem background tend to think that we can predict… Read More
  • Drug Industry History

    Ancient Modeling

    I really got a kick out of this picture that Wavefunction put up on Twitter last night. It’s from a 1981 article in Fortune, and you’ll just have to see the quality of the computer graphics to really appreciate it. That sort of thing has hurt computer-aided drug design a vast amount over the years. Read More
  • Drug Development

    Predicting What Group to Put On Next

    Here’s a new paper in J. Med. Chem. on software that tries to implement matched-molecular-pair type analysis. The goal is a recommendation – what R group should I put on next? Now, any such approach is going to have to deal with this paper from Abbott in 2008. In that one, an analysis of 84,000… Read More
  • In Silico

    Computational Nirvana

    Wavefunction has a post about this paper from J. Med. Chem. on a series of possible antitrypanosomals from the Broad Institute’s compound collection. It’s a good illustration of the power of internal hydrogen bonds – in this case, one series of isomers can make the bond, but that ties up their polar groups, making them… Read More
  • Drug Assays

    Ligand Efficiency: A Response to Shultz

    I’d like to throw a few more logs on the ligand efficiency fire. Chuck Reynolds of J&J (author of several papers on the subject, as aficionados know) left a comment to an earlier post that I think needs some wider exposure. I’ve added links to the references: An article by Shultz was highlighted earlier in… Read More
  • Biological News

    “It Is Not Hard to Peddle Incoherent Math to Biologists”

    Here’s a nasty fight going on in molecular biology/bioinformatics. Lior Pachter of Berkeley describes some severe objections he has to published work from the lab of Manolis Kellis at MIT. (His two previous posts on these issues are here and here). I’m going to use a phrase that Pachter hears too often and say that… Read More
  • In Silico

    A New Metabolism Predictor

    Drug metabolism is a perennial topic for us small-molecule people. Watching your lovingly optimized molecules go through the shredding-machine of the liver is an instructive experience, not least when you consider how hard it would be for you to do some of the chemistry that it does. (For reference and getting up to speed on… Read More
  • In Silico

    Picking Diverse Compounds

    Diversity deck, diversity set, diversity collection: most chemical screening efforts try to have some bunch of compounds that are selected for being as unlike each other as possible. Fragment-based collections, being smaller by design, are particularly combed through for this property, in order to cover the most chemical space possible. But how, ex… Read More